Trial Profile
Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2019
Price :
$35
*
At a glance
- Drugs Basiliximab (Primary) ; Infliximab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 03 Apr 2019 Status changed from active, no longer recruiting to discontinued.
- 28 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
- 28 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.